ARS Pharmaceuticals' neffy faces slow adoption and insurance hurdles but shows potential for significant market share and revenue. Read why SPRY stock is a Buy.
AAP Newsroom on MSN
More work for Labor as borrowers brace for rate rise
The benchmark borrowing rate has been lifted to an 18-year high in a widely-anticipated decision by the Reserve Bank of Australia on Melbourne Cup day.
Get savings rates that surpass the national average ...
10h
V2X lifts 2026 outlook to $4.95B-$5.1B revenue as it expects EPS and free cash flow growth in 2027
V2X Q3 2026 earnings: revenue rose 9%, guidance increased, and 2027 margin outlook improved despite Middle East risks.
After helping thousands through Hurricane Lala, Vibrant Hawaiʻi wants Green Fee money to build hubs statewide.
Worksport built inventory during the first half of 2026 to support its product launches and distribution expansion. In the third quarter, the Company began converting that inventory into sales and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results